|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 11, 2017 ) The global orthobiologics market is projected to reach USD 6.06 Billion by 2022 from USD 4.66 Billion in 2017, at a CAGR of 5.4% during the forecast period. Factors such as rising burden of orthopedic injuries; increasing incidence of sports injuries and road accidents; increasing incidence of spinal fusion surgeries; risk factors associated with increasing aging population, obesity rate, & high incidence of musculoskeletal disorders; and growing patient preference for minimally invasive procedures are driving the orthobiologics market.
http://www.marketsandmarkets.com/Market-Reports/orthobiologics-market-162747970.html
This report broadly segments the orthobiologics market into product, application, and end user. On the basis of product, the market is categorized into allografts, synthetic orthobiologics, PRP, BMAC, DBM, BMP, and viscosupplementation products. In 2017, the viscosupplementation products segment is expected to account for the largest share of the market. The large share of this segment can be attributed to the increasing incidence of osteoarthritis of the knee and hip joints among the baby boomer population and lower cost of viscosupplementations.
Based on application, the market is segmented into fracture recovery, osteoarthritis & degenerative arthritis, spinal fusion, soft-tissue injuries, and maxillofacial & dental applications. The osteoarthritis & degenerative arthritis segment is estimated to command the largest share of the global orthobiologics market in 2017. The large share of this segment is mainly due to factors such as the significant rise in target patient population across major markets, rising public awareness related to clinical side effects associated with oral medications for pain management, clinical advancements in OA management methodologies, robust healthcare infrastructure & facilities for specific joint replacement surgeries across major markets, and growing clinical evidence validating the efficacy of biologics in OA treatment.
Request Sample Pages@ http://www.marketsandmarkets.com/requestsample.asp?id=162747970
On the basis of end user, the market is segmented hospitals, orthopedic clinics, and ambulatory care centers; research & academic institutes; and dental clinics and facilities. The hospitals, orthopedic clinics, and ambulatory care centers segment is poised to grow at the fastest rate during the forecast period. This can be attributed to the growing geriatric population (coupled with the increasing number of spinal fusion surgeries performed); road accident injuries and bone fractures; growing prevalence of spinal disorders; and growing awareness of products.
The report covers the orthobiologics market across four major geographies, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to command the largest share of the market in 2017 due to the increasing incidence of spinal disorders, rising geriatric and obese population, growing preference for minimally invasive procedures, and growing physician and patient awareness about newly introduced treatment procedures and technologies. However, Asia Pacific is expected to register the highest growth rate during the forecast period. The presence of a large geriatric and target patient population, high incidence of osteoarthritis and obesity, increasing government spending on healthcare, and improving healthcare infrastructure are some of the major factors driving the growth of the Asia Pacific orthobiologics market.
On the other hand, the high cost associated with orthobiologics-based treatments is the major factor restraining the growth of this market.
Some of the major players operating in this market are Medtronic, DePuy Synthes, and Zimmer Biomet. The other players in this market include Bioventus, Arthrex, Harvest Technologies, Globus Medical, Orthofix International, and RTI Surgical.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
MarketsandMarkets
Mr. Rohan
1-888-600-6441
sales@marketsandmarkets.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
